Vivos Inc

    • Moat Score
    • Market Cap $57.26M
    • PE -18
    • Debt -
    • Cash $3.27M
    • EV -
    • FCF -

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$3.19M
    EBIT-$2.88M
    ROE-100%
    ROA-87%
    Equity$3.19M
    Growth Stability1
    PE-17.97
    PB17.97
    P/S2.1K
    Price/Cash0.06
    Net Margins-3K%
    Gross Margins-123%
    Op. Margins-11K%
    Sales Growth YoY494%
    Sales Growth QoQ-249%
    Sales CAGR7%
    Equity CAGR5%
    Earnings Growth YoY49%
    Earnings Growth QoQ-18%
    Sales CAGR 5Y12%
    Equity CAGR 5Y39%
    Earnings CAGR 3Y-29%
    Sales CAGR 3Y-29%
    Equity CAGR 3Y19%
    Market Cap$57.26M
    Revenue$27.24K
    Assets$3.30M
    Cash$3.27M
    Shares Outstanding448.23M
    Moat Score0%
    Working Capital3.19M
    Current Ratio28.62
    Gross Profit-$33.57K
    Shares Growth 3y9%
    Equity Growth QoQ48%
    Equity Growth YoY144%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

    SEC Filings

    Direct access to Vivos Inc (RDGL) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2025
      • 10-Q Mar 31
    • 2024
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2023
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31

    Sector Comparison

    How does Vivos Inc compare to its competitors?

    Not enough data to generate a comparison chart between Vivos Inc and its competitors. Please check back later.

    Peter Lynch's Chart

    This chart shows the current pricing of Vivos Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Vivos Inc Discounted Cash Flow

    Fully customizable DCF calculator online for Vivos Inc.

    0
    012345678910TV
    fcf$0$0$0$0$0$0$0$0$0$0$0$0
    DCF$0$0$0$0$0$0$0$0$0$0$0
    Value$0

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
    Net Margins26K%-122K%-158K%--17K%-14K%-17K%-7K%-15K%-58K%-3K%
    ROA--9K%-16K%-12K%-3K%-71%-153%-142%-173%-117%-87%
    ROE-57%151%818%109%-3K%-172%-149%-212%-136%-100%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
    Debt over FCF-----------
    Debt over Equity-0.12-0.03-0.6-0.06-0.293.35-----
    Growth Stability----------1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
    Revenue YoY growth--66%-50%---26%113%145%-47%-74%12%
    Earnings YoY growth--258%-35%20%-79%-41%164%-2%17%1%-
    Equity YoY growth-20%-75%-78%57%-102%4K%13%-18%57%39%
    FCF YoY growth-----------